PC
KZR

PA Capital’s Kezar Life Sciences KZR Stock Holding History

PA Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$116K Buy
+2,390
New +$114K 0.08% 166
2020
Q1 		– Sell
-1,976
Closed -$79K – 173
2019
Q4 		$79K Buy
+1,976
New +$60.8K 0.07% 127

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PA Capital's KZR Position: Q3 2020 in Review

PA Capital opened a new position in Kezar Life Sciences (KZR) in Q3 2020: 2,390 shares worth $116K. The stake represents 0.08% of the portfolio and ranks #166 among its holdings. This is a return to the name: PA Capital previously reported a position in KZR as recently as Q4 2019.

PA Capital first reported a position in KZR in Q4 2019 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold KZR as of Q3 2020.

  • PA Capital held 2,390 shares of Kezar Life Sciences worth $116K as of Q3 2020.
  • Kezar Life Sciences was a new PA Capital position in Q3 2020.
  • Kezar Life Sciences made up 0.08% of PA Capital's portfolio in Q3 2020, its #166 holding.
  • PA Capital first reported a position in Kezar Life Sciences in Q4 2019 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.